Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing
strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre …

Abstract Twenty-nine British and Irish hospitals each collected up to 300 bacterial isolates
from in-patients. The organisms were identified by an appropriate API system or, for …

Objectives To use a pre-clinical infection model to assess the antibacterial effect of human
simulations of dosing with ceftolozane/tazobactam (with or without amikacin) or meropenem …

The pharmacokinetics–pharmacodynamics (PK–PD) breakpoint of piperacillin/tazobactam
(PIPC/TAZ) for hospital-acquired pneumonia (HAP) and Pseudomonas aeruginosa-induced …

Combination with tazobactam substantially enhanced the activity of piperacillin against
routine isolates of staphylococci, various Enterobacteriaceae, Acinetobacter anitratus, and …

Despite β-lactamase inhibitors being available for clinical use for nearly 30 years, a paucity
of data exists describing the pharmacokinetic-pharmacodynamic (PK-PD) determinants of …

Piperacillin/tazobactam is a new drug consisting of a highly active penicillin and a beta-
lactamase inhibitor. Pharmacokinetic variables of both components after they have been …

Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections
in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children …

Piperacillin–tazobactam is a β-lactam/β-lactamase inhibitor combination with a broad
spectrum of antibacterial activity that includes Gram-positive and-negative aerobic and …

A better dosing strategy can improve clinical outcomes for patients. We systematically
reviewed the literatures to determine whether any clinical benefits exist for piperacillin …